Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics

Next Previous
Drug Profile

Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics

Alternative Names: NEPHSTROM ORBCEL-M; ORBCEL-M; REDDSTAR ORBCEL-M

Latest Information Update: 24 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orbsen Therapeutics
  • Developer Mario Negri Institute for Pharmacological Research; Orbsen Therapeutics
  • Class Mesenchymal stem cell therapies; Stem cell therapies; Uroprotectives
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic nephropathies
  • Phase I Diabetic foot ulcer

Most Recent Events

  • 24 Jul 2023 Allogeneic bone marrow-derived mesenchymal stromal cell therapy is still in phase Ib trials for Diabetic foot ulcer in Denmark (Topical) (EudraCT2015-005580-16) (Orbsen Therapeutics pipeline, July 2023)
  • 26 Jan 2023 Orbsen Therapeutics plans a adaptive phase IIb trial for patients with Diabetic nephropathies
  • 26 Jan 2023 Efficacy and adverse events data from a NEPHSTROM phase I/II trial in patients with Diabetic nephropathies released by Orbsen Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top